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INTRODUCTION 
 
Sarcomas represent a third of all malignant solid tumors in children and adolescents. 
The most common histological types are rabdomyosarcoma, osteosarcoma, and Ewing's 
sarcoma [1]. Approximately 60% of these lesions are found in bones or soft tissues of 
the extremities [2]. These tumors types have a high systemic dissemination capacity, 
and over 70% will have macro or microscopic metastases at the time of diagnosis. This 
implies that a combined local and systemic treatment is needed in order to reach a 
definitive control of the disease [3]. 
 
Multidisciplinary treatment has been employed since the 1970s, combining surgery, 
radiotherapy, and chemotherapy. Contemporary survival rates in patients with localized 
disease have been reported in the range of 65-75% for Ewing's sarcoma [4-7] and 65-
90% for osteosarcoma [8,9]. 
 
Local treatment of bone sarcomas of the extremities has undergone a considerable 
change in recent years. The tendency towards radical tumor surgical removal with 
amputation [11-13] has given way to programs with extremity preservation by 
combining surgery and neoadjuvant and adjuvant radiation therapy and chemotherapy 
without compromising the results in disease-free survival [14-16]. 
 
Intraoperative radiotherapy (IORT), is a treatment technique with the aim to sterilize 
surgically non-resected neoplastic tissue, by releasing a high dose of radiation into the 
tumor bed area. Some normal structures, organs, and tissues can be shielded or kept out 
of the irradiation field [16-19]. 
 
IORT seeks to exploit the therapeutic index by improving control over the local spread 
of the tumor, protecting the normal, non-affected tissues, and/or increasing the 
biological efficacy of irradiation after surgical debulking of the tumor [20]. 
 
Our experience using IORT in bone sarcoma patients of pediatric age is reported. 
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MATERIAL AND METHODS  
 
Patients 
 
From September 1984 to December 1989, forty-five pediatric and adolescent patients 
with bone sarcomas of the extremities had entered into the prospective treatment 
protocol at the University Clinic of Navarra and received intraoperative radiotherapy 
(IORT) as a part of the multidisciplinary treatment approach. During this period a total 
of 51 pediatric-age patients with localized bone sarcomas were studied and treated in 
our institution. Five malignant fibrous histiocytomas were not analyzed in this report. 
One extensive Ewing's sarcoma localized in the foot was amputated as the initial radical 
local treatment. 
 
Patients analyzed in this report were required to meet the following criteria: 1) 
histologically proven bone sarcoma diagnosis; 2) younger than 21 years; and 3) no 
evidence of metastatic disease at the time of diagnosis. Seven patients were excluded 
due to the presence of metastasis at the time of diagnosis. 
 
Thirty-eight patients were analyzed: 22 osteosarcomas and 16 Ewing's sarcomas. Sex 
distribution showed 19 males and 19 females. Ages ranged from 4 to 21 years (median: 
13 years). Five tumors were located in the upper extremity, 29 in the lower extremity, 
and 4 involved central anatomical structures. Thirty-four patients had primary disease 
(90%) and 4 local tumor recurrences (10%). 
 
The patient characteristics by histological tumor types are detailed in Table I. 
 
The pathology report classified the following osteosarcoma subtypes: chondroblastic 
[6], osteoblastic [11], fibroblastic [1], mixed [2], and other histologies [1]. Tumor 
characteristics are listed in Table II. 
 
Staging procedures included computed tomography (CT) of the primary site, chest, and 
liver; bone scan and radiography of the chest and primary bone involved. The size of the 
primary tumor was measured on the pretherapy CT scan: tumor volumes were assumed 
to be cylindrical. The larger tumor dimension became the length of the cylinder while 
the smaller tumor dimension became the diameter, according to measure method 
described by Sailer et al. [4]. 
 
Before the initiation of the protocol, all patients were fully informed and full consent 
was obtained. 
  
 
OSTEOSARCOMA PROTOCOL 
 
Twenty-two patients entered this protocol, which included neoadjuvant chemotherapy 
with three cycles with intra-arterial cisplatinum and systemic doxorubicin, repeated 
every 3 weeks and followed by a wide surgical en bloc tumor-bearing resection, with an 
IORT boost (10-20 Gy) to the tumor bed area. 
 
Three weeks after surgery, adjuvant chemotherapy was given using three alternating 
regimens, —cisplatinum-adriamycin, high-dose methotrexate, and bleomycin-
cyclophosphamide-vincristine-actomycin D— and it was maintained for 48 weeks 
[21,22]. 
 
Four patients received external beam radiotherapy because of macroscopic residual 
postsurgical disease: 46 Gy [3] and 50 Gy [1]. Another patient received preoperative 
external beam radiotherapy for a large primary tumor (25 Gy). 
  
 
Ewing's Sarcoma Protocol 
 
Primary disease. Preoperative, concurrent systemic chemotherapy and radiotherapy 
were used. Alternating courses of two regimens were used, containing adriamycin, 
methotrexate, cyclophosphamide, vincristine (regimen 1), and bleomycin, 
cyclophosphamide, actinomycin D, vincristine (regimen 2), every 3 weeks. 
 
External beam radiotherapy has been delivered to a volume encompassing the entire 
bone and a 3-5 cm margin beyond the known soft tissue extension. The total dose 
administered has been 45-50 Gy, 1.8-2 Gy per fraction, 5 fractions per week. 
 
Four to six weeks after completion of preoperative radiotherapy, patients were 
considered for surgery and an IORT boost (10-20 Gy) delivered to the residual tumor or 
tumor bed area.  
 
After surgery, alternating multiagent chemotherapy was maintained according to the T11 
protocol described by Rosen et al. [6] for 1 year. 
 
 
Recurrent disease. Four patients with local recurrence received a reinduction course of 
sytemic chemotherapy followed by surgical resection plus a single IORT dose of 20 Gy 
in the tumor bed. 
 
All patients had previously received a radical dose of external beam radiotherapy. 
Systemic chemotherapy was given as adjuvant therapy for 1 year or until the 
development of disease progression. 
 
 
 
Surgery 
 
Conservative surgery with limb-sparing techniques was performed on all patients: 
anatomic locations and radiologic extension of the tumor permitted in most cases wide 
excision without a severe final disability. 
 
The methodology included a wide surgical en bloc tumor-bearing resection by removing 
all the involved bone and a macroscopic margin of normal surrounding tissues. It was 
considered radical if the margins of resection were free of tumor and if the tumor-
bearing bone had been completely resected. Macroscopic residual disease was 
considered if evidence of disease in the margins of resection or on tumor bed area was 
present. Treatment characteristics by histological group are related in Table III. 
 
 
Intraoperative Radiotherapy (IORT) 
 
IORT was carried out using a linear accelerator (Mevatron 77). Single or multiple fields 
were used depending on anatomic location and size of the tumor bed area. Cone size 
ranged from 5 to 12 cm in diameter. The electron beam energy ranged from 6 to 20 Gy, 
and it was selected depending on the tumor burden after surgery and normal tissues 
included in the field (Table IV). The IORT single dose ranged from 10 to 20 Gy. The 
dose was adopted depending on histologic subtype, initial tumor size, and amount of 
postsurgical residual disease: Ewing's sarcomas were treated generally with 10 or 15 
Gy, while osteosarcoma postresected tumor bed received 15 Gy (microresidue) or 20 
Gy (macroresidue). This was a case-by-case decision. 
 
The planning of each treatment program was performed by computer using a dosimetric 
system able to handle data and results from radiation beam calibration as well as the CT 
scan images. 
 
 
Survival and Local Control Evaluation 
 
Survival has been calculated from the date of initial treatment until death or last follow-
up. Disease-free of local recurrence was measured from the date of initial treatment to 
the date of local relapse (within radiation field). Disease-free survival was measured 
from the date of initial treatment to confirmation of tumor relapse. 
 
 
Statistical Analysis 
 
Estimates of survival and survivorship free of recurrence were calculated by the Kaplan-
Meier methods [23] using the BMDP statistical package. 
 
 
RESULTS 
 
Results for the Overall Group 
 
Thirty-eight patients have been evaluated including 22 osteosarcomas and 16 Ewing's 
sarcomas. The median follow-up time was 25 months (2-65+ months). The projected 3-
year disease-free of local recurrence has been 93%. Two patients relapsed locally. The 
projected 5-year disease-free survival and the overall survival for the entire group have 
been 65% and 69%, respectively (Fig. 1). 
 
 
Patterns of Failure and Survival in Osteosarcoma 
 
Twenty-two patients with osteosarcoma have been treated and evaluated. In all cases 
extracompartmental involvement was present in the primary tumor, together with 
invasion of the surrounding soft tissues. The median follow-up time is 18 months (3+-
52+ months). Four out of 22 patients (18%) had relapses. All of these occurred during 
the first 2 years after the initial treatment: 3/22 (18%) developed lung metastasis. One 
out of 22 patients (chondroblastic type) had a local recurrence and distant lung 
metastasis 13 months after IORT. 
The 3-year projected actuarial disease-free of local recurrence and disease-free survival 
rates are 93% and 78%, respectively. The projected actuarial survival is 87%. 
 
Twenty out of 22 patients are alive: 18/22 (81%) with no evidence of disease and 2/22 
(9%) with metastatic disease. Two patients died from disease progression (Tables V, 
VI). 
 
 
Patterns of Failure and Survival in Ewing's Sarcoma 
 
Sixteen patients with Ewing's sarcoma, primary [12] and recurrent [4], have been 
evaluated, with an overall median follow-up time of 24 months (3-65+ months).  
  
Five out of 16 patients (31%) (three primary and two recurrent) have relapsed. All 
developed metastatic disease progression. One local failure was identified in a patient 
with cervical vertebral primary. 
 
The projected 5-year actuarial disease-free of local recurrence, disease-free survival, 
and overall survival were 93%, 58%, and 57%, respectively. 
 
Nine out of 16 patients are disease free (22+-65+ months) and 1 patient is alive with 
metastatic disease. 
 
 
Toxicity and Complications 
 
For the purpose of the present analysis, only those observations that might be related to 
IORT, or the combination of IORT with surgery and/or external beam irradiation, will 
be described. 
 
At the time of the IORT procedure structures such as great vessels or nerves were 
mobilized or protected whenever it was possible. 
 
 
Early Morbidity 
 
Any toxic episode or complication that occurred before 3 months from IORT was 
considered early morbidity. Four patients had postoperative local infection requiring 
surgical management and removal of prosthetic devices. No further sequelae were 
observed. 
 
 
Late Morbidity 
 
Any complication after 3 months from IORT was considered late morbidity.  
 
The final result regarding functional impairment was classified according to degree of 
functional limitation, cosmetic or radiological abnormality, dysmetry, atrophy, and 
peripheral neuropathy (pain, loss of sensitivity, motor deficit). 
Three patients had delayed wound healing and severe soft tissue necrosis: two patients 
were repaired with a myocutaneous flap, and another one required amputation after 
failure of several reconstructive and repair procedures. 
 
Seven out of 38 patients (18%) presented some degree of soft tissue fibrosis and 16/38 
patients (42%) had a mild to moderate degree of functional disability of the treated 
extremity. These findings were established from 6 to 12 months after IORT treatment, 
and were improved by an intense rehabilitation training program. No severe 
contractures were observed. 
 
Six out of 38 patients (16%) had extremity dysmetry: three of them had a shortening >3 
cm. All six patients received boost doses of IORT of 10 Gy [1], 15 Gy [3], and 20 Gy 
[2], and three were treated with additional external beam radiotherapy (46-50 Gy). 
Seven patients presented some degree of atrophy of the extremity treated. 
 
Finally, 3/38 (8%) patients developed a symptomatic peripheral neuropathy which 
occurred 9 to 13 months after IORT treatment. The associated symptoms were motor 
deficit, loss of discriminant sensitivity, and chronic pain. None of these cases had 
protection of the nerves from the IORT beam: the sciatic, femoral, and internal popliteal 
sciatic nerves were included in the IORT field and received 15 Gy [2] and 20 Gy [1]. 
 
Two patients showed some recovery from motor deficit starting 14 to 16 months after 
IORT. Chronic pain was acceptably controlled by carbamazepine, nonsteroid 
analgesics, and anti-inflammatory compounds (Table VII). 
 
 
DISCUSSION 
 
Local control is an essential requirement for the successful treatment of extremity bone 
sarcoma patients. This means that the planning of local and regional treatment must be 
carefully designed, taking into account in each individual case, the possible surgical 
options and the established chemotherapy and radiotherapy management. Factors of 
recognized prognostic value such as tumor stage and volume, location and involvement 
of the vasculo-nervous structures, presence of pathological fracture, histological grade 
of malignity, etc., have to be considered for treatment planning [24-28]. 
 
The multidisciplinary approach has brought significant advances in the local control of 
bone sarcomas, which allows more conservative attitudes in planning surgery, without 
detriment to the long-term survival rates [13,29,30]. 
 
The addition of neoadjuvant treatment (chemotherapy with or without radiotherapy) to 
surgery and conservative surgery of the extremity have made possible, in many cases, 
tumor resection en bloc with functional reconstruction with prosthetic devices or 
allograft [31,32]. 
 
Intra-arterial administration of chemotherapy in osteosarcoma has been shown to induce 
necrosis of malignant tissue with a marked reduction and delimitation in the tumor 
mass, thus facilitating later resection surgery [33]. 
 
Through the combination of high-dose chemo- and radiotherapy is possible to achieve 
up to 70% local control in Ewing's sarcoma of the extremities [5,6]. These figures are 
apparently improved by adding surgery to the treatment management, although it might 
be compromised in tissues which have received high irradiation doses (over 50 Gy) 
[26]. 
 
Intra-arterial chemotherapy and high dosage irradiation covering large anatomical areas 
implies a rise in toxicity in the healthy tissues surrounding the tumor which jeopardizes 
the normal development of the extremity, but does rescue some patients with local 
disease recurrences [34]. 
 
Local recurrence is noted in 10% to 30% of patients receiving combined treatment. It is 
most frequently seen in chondroblastic osteosarcoma, and Ewing's sarcoma of proximal 
locations [27,28]. 
 
IORT is emerging as an interesting alternative in the attempt to sterilize the tumor bed 
from possible microscopic disease which remains behind at the time of maximum 
surgical debulking, by giving a single high dose of fast electrons (15-20 Gy) with high 
biological activity and cytotoxic strength [20]. 
 
In the field of pediatric oncology, IORT appears as an, interesting alternative to the use 
of extensive external radiation areas [35]. In selected patients it seems feasible to 
combine IORT (10-15 Gy) with external radiation at doses lower than have classically 
been considered optimal (15% to 25% reduction), thus reducing toxicity in healthy 
tissues. On the other hand, it also allows a therapeutic dose to be given in some 
anatomic locations with low tolerance to external radiation (e.g., paravertebral or 
retroperitoneal lesions) because of the proximity to highly radiosensitive critical tissues. 
It has also been shown as a suitable treatment modality for delivering a boost dose 
[36,37]. 
 
In our experience, IORT is technically feasible in patients of pediatric age with locally 
advanced bone sarcomas. Only 2/38 patients had a local progression. The projected 3 
year disease-free of local recurrence rate has been 93%. 
 
Acute complications related to IORT in the immediate postoperative period have not 
been detected. Single doses of 10-20 Gy can be used on the extremities with safety. Pre- 
or postoperative external beam radiotherapy (45-60 Gy) in addition to IORT seems to 
increase the frequency and severity of toxicities, such as local soft tissue necrosis, 
peripheral neuropathy, and/or the development of long-term fibrosis of the soft tissues. 
 
The peripheral nerves are dose-limiting structures to IORT [38]. Neuropathies have 
been reported after IORT treatment of retroperitoneal and pelvic tumors [39,40]. 
 
The tolerance of the tissues as well as the toxicity and late morbidity of IORT trials 
must be carefully evaluated and reported [41]. This is of particular importance in 
pediatric patients. 
 
Intraoperative radiotherapy seems to be an interesting treatment modality to promote 
local control in advanced primary or recurrent bone sarcomas not amenable to complete 
surgical resection. It appears to be an interesting approach to be considered in the 
management of limb-sparing surgery. Further efforts have to be made to reduce late 
morbidity of the extremity. 
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Table 1. Patient Characteristics 
 Osteogenic sarcoma Ewing's sarcoma 
No. of patients 22 16 
Age (yr)   
Median 11 14 
Range 6-19 4-21 
Sex   
Male 10 9 
Female 12 7 
Karnofsky   
≥ 70 % 16 12 
< 70 % 6 4 
Median follow-up 18 months 20 months 
Range (3+-52+) (2-65+) 
 
 
 
Table 2. Tumor Characteristics 
Tumor Osteogenic sarcoma Ewing's sarcoma 
Involved bones   
Extremity   
Humerus 3 1 
Femur 14 3 
Tibia 5 4 
Fibula  3 
Radium  1 
Central   
Vertebra  2 
Pelvis  2 
Tumor size (cm
3
)   
≤ 300 13 9 
> 300 9 7 
Type of disease   
Primary 22 12 
Recurrent  4 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Treatment Characteristics 
Treatment Osteogenic sarcoma Ewing's sarcoma 
 No. (%) No. (%) 
Chemotherapy     
Neoadjuvant chemotherapy 22 (100) 16 (100)
a
 
Adjuvant chemotherapy 22 (100) 16 (100)
a
 
Surgery     
Macroscopic residual disease 4 (18) 5 (31) 
Microscopic residual disease 18 (81) 11 (69) 
Radiotherapy     
Preoperative 1 (4) 5 (31) 
Postoperative 4 (18) 3 (18) 
Pre- and postoperative ―  3 (18) 
a
 4/15 (26 % ) recurrences received reinduction chemotherapy 
 
 
 
Table 4. IORT Treatment Characteristics 
IORT Osteogenic sarcoma Ewing's sarcoma 
Cone  size (cm)   
5-8 8 11 
9-12 19 10 
Electron energy (MeV)   
6-9 21 15 
12-20 6 6 
Total dose (Gy)   
10 5 11 
15 13 9 
20 9 1 
No. of fields   
Single 17 13 
Multiple 5 3 
a
Osteogenic sarcoma: 5 patients were treated with a double Ewing's 
sarcoma: 2 patients were treated with a double field and 1 patient was 
treated with four consecutive fields 
 
 
 
 
 
 
Table 5. Patterns of Failure* 
Disease LF LF + DM DM 
Osteosarcoma 0/22 1/22 3/22 
Ewing’s sarcoma    
Primary 0/12 1/12 2/12 
Recurrent 0/4 0/4 2/4 
*LF, local failure; DM, distant metastasis. 
 
 
Table 6. Local control and Patient Outcome* 
Disease No. patients MFT (mo) 
Local 
control 
Patient’s status 
(alive/dead) 
Osteosarcoma 22 18+ 21/22 (95%)  20/2 
Ewing’s sarcoma     
Primary 11 35+ 11/12 (92%) 10/2 
Recurrent 4 12 4/4 (100%) 0/4 
*MFT = median follow up time (mo) 
 
 
Table 7. Late Morbidity Due to the Treatment Program Including the Possible IORT 
Contribution 
Toxicity IORT 
(Gy) 
EBR 
(Gy) 
Outcome 
Delayed wound healing 
and necrosis 
10 10 (preop) Reversible-myocutaneous 
flap  46 (postop) 
Delayed wound healing 
and necrosis 
15 10 (preop) Reversible-myocutaneous 
flap  46 (postop) 
Delayed wound healing and 
necrosis 
10 10 (preop) Amputation 
 46 (postop)  
Severe fibrosis 15 46 Loss of movement at hip 
Severe fibrosis + peripheral 
neuropathy 
15 ― Slowly reversible at 14 months 
Severe fibrosis + peripheral 
neuropathy 
15 ― Slowly reversible at 16 months 
Peripheral neuropathy 20 ― No recovery 
Shortening  > 3 cm 10 46 Modera te disability 
Shortening  > 3 cm 20 ― Modera te disability 
Shortening  > 3 cm 15 50 Severe disability 
*EBR = external beam radiotherapy; preop = preoperative single dose with external beam 
photons; postop = postoperative fractionated irradiation.  
 
 
 
Figure 1. Disease-free survival, disease-free of local recurrence, and overall survival for 
the entire group. 
